Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 801–900 of 1,019
PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
Kheirkhah, A., Lamina, C., Kollerits, B., Schachtl‐Riess, J. F., Schultheiß, U. T., Forer, L., Sekula, P., Kotsis, F., Eckardt, K., & Kronenberg, F. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01230122 · Cited by 26
Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis
Nguyen, T. K., Paone, S., Chan, E., Poon, I. K. H., Baxter, A. A., Thomas, S. R., & Hulett, M. D. (2022) · Cells · doi:10.3390/cells11203198 · Cited by 27
“It has been reported in two phase 3 clinical trials that measured efficacy and safety that two monoclonal antibodies inhibiting PCSK9, evolocumab and alirocumab, significantly lowered LDL-cholesterol by approximately 60% and reduced the incidence of cardiovascular events [68,71,72].”
BackgroundMa, M., Hou, C. J., & Liu, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148486 · Cited by 26
MicroRNAs regulating apolipoprotein B-containing lipoprotein production
Zhou, L., Irani, S., Sirwi, A., & Hussain, M. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.020 · Cited by 27
Familial Hypercholesterolemia: Advances in Recognition and Therapy
Cartier, J. L., & Goldberg, A. C. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.006 · Cited by 29
Anti-inflammatory drugs as promising cardiovascular treatments
Huet, F., Akodad, M., Fauconnier, J., Lacampagne, A., & Roubille, F. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1273771 · Cited by 26
“inhibition may improve cardiovascular events [107] without any effect on hs-CRP [108].”
BackgroundNew Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Genetic Polymorphisms in Sepsis and Cardiovascular Disease
Nakada, T., Takahashi, W., Nakada, E., Shimada, T., Russell, J. A., & Walley, K. R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.01.003 · Cited by 26
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
“Data from trials of PCSK9 inhibitors have also suggested an association with neurocognitive problems albeit with a very low absolute incidence [58,78].”
BackgroundKhan, S. U., & Michos, E. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100013 · Cited by 26
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 28
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
Rivera, F. B., Cha, S. W., Linnaeus Louisse, C., Carado, G. P., Magalong, J. V., Tang, V. A., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2024.101549 · Cited by 25
Wang, Q., Chen, Z., Lü, X., Lin, H., Feng, H., Weng, N., Chen, L., Liu, M., Li, L., Huang, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202501623 · Cited by 29
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia
Xie, X., Shi, X., Zhang, Y., Su, S., Jiang, C., Liu, M., Wang, J., Peng, D., Lv, L., Chai, X., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.008 · Cited by 27
White, C. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015608487 · Cited by 26
Kastelein, J. J. P., Kereiakes, D. J., Cannon, C. P., Bays, H. E., Minini, P., Lee, L. V., Maroni, J. M., & Farnier, M. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000438 · Cited by 26
Self-citationJacobson, T. A., Khan, M. A. S., Maki, K. C., Brinton, E. A., & Cohen, J. D. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.006 · Cited by 25
Akin, A. C., Barrila, M. T., Brandt, T. A., Dechert‐Schmitt, A. R., Dubé, P., Ford, D. D., Kamlet, A. S., Limberakis, C., Pearsall, A., Piotrowski, D. W., et al. (2017) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00304 · Cited by 26
Coca, A., Kreutz, R. H., Manolis, A. J., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002464 · Cited by 27
Sánchez-Pérez, H., Quevedo-Abeledo, J. C., Tejera-Segura, B., de Armas-Rillo, L., Rúa-Figueroa, Í., González-Gay, M., & Ferraz-Amaro, I. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20975904 · Cited by 19
Page, M. M., Stefanutti, C., Sniderman, A. D., & Watts, G. F. (2015) · Clinical Science · doi:10.1042/cs20140755 · Cited by 26
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Wong, M. G., Wanner, C., Knight, J. F., & Perkovic, V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv393 · Cited by 28
Feng, Z., Li, H., Bei, W., Guo, X., Wang, K., Yi, S., Luo, D., Li, X., Chen, S., Ran, P., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22712 · Cited by 25
Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons
Bajaj, N. S., Patel, N., Kalra, R., Ahmad, A., Venkatraman, A., Arora, G., & Arora, P. K. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx037 · Cited by 25
Bai, J., Gong, L., Li, Q., & Wang, Z. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.004 · Cited by 26
Lipid-lowering treatment in peripheral artery disease
Katsiki, N., Giannoukas, A. D., Athyros, V. G., & Mikhailidis, D. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.003 · Cited by 27
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
Leiter, L. A., Tinahones, F. J., Karalis, D. G., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., & Jones, P. H. (2018) · Diabetic Medicine · doi:10.1111/dme.13817 · Cited by 25
AlTurki, A., Marafi, M., Dawas, A., Dubé, M., Vieira, L., Sherman, M. H., Grégoire, J. C., Thanassoulis, G., Tardif, J., & Huynh, T. T. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.011 · Cited by 25
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
Warden, B. A., Miles, J., Oleaga, C., Ganda, O. P., Duell, P. B., Purnell, J. Q., Shapiro, M. D., & Fazio, S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100012 · Cited by 25
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Ito, M., Hiwasa, T., Oshima, Y., Yajima, S., Suzuki, T., Nanami, T., Sumazaki, M., Shiratori, F., Funahashi, K., Li, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708039 · Cited by 25
“ODYSSEY investigators conducted a randomized trial involving for 2341 patients and demonstrated that alirocumab showed significantly reduced LDL cholesterol levels (11).”
MethodScudeler, T. L., da Costa, L. M. A., Nunes, R. A. B., Schneidewind, R. O., Brito, T. M., Pereira, D. C. G., de Oliveira, R. P., Santana, G., Castello, H. J., Cantarelli, M. J. D. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80578-w · Cited by 25
Bococizumab for the treatment of hypercholesterolaemia
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1279602 · Cited by 26
Pirro, M., Bianconi, V., Francisci, D., Schiaroli, E., Bagaglia, F., Sahebkar, A., & Baldelli, F. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13273 · Cited by 25
“In the post hoc analysis of the ODYSSEY LONG TERM study, alirocumab reduced the combined end-point of death from coronary artery disease, non-fatal myocardial infarction, fatal or non-fatal ischaemic stroke or unstable angina requiring hospitalization, as compared with placebo in patients with hypercholesterolaemia on…”
MethodCurrent pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 26
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
Oleaga, C., Hay, J., Gurcan, E., David, L. L., Mueller, P. A., Tavori, H., Shapiro, M. D., Pamir, N., & Fazio, S. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000964 · Cited by 25
“PCSK9 plays a key role in lipoprotein metabolism (11, 12) and is a therapeutic target to lower plasma LDL-C levels in high-risk individuals (13, 14).”
BackgroundEnnezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 25
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Fusco, S. A. D., Maggioni, A. P., Bernelli, C., Perone, F., Marzo, V. D., Conte, E., Musella, F., Uccello, G., Luca, L. D., Gabrielli, D., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311375 · Cited by 26
“PCSK9 inhibitor monoclonal antibodies lower LDL-C by 50–60% and reduce the risk for CVD proportionally to the LDL-C reduction obtained [4,5].”
BackgroundHypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective
Shang, G., Shao, Q., Lv, K., Xu, W., Ji, J., Fan, S., Kang, X., Cheng, F., Wang, X., & Wang, Q. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01217-3 · Cited by 26
Franchini, M., Capuzzo, E., & Liumbruno, G. M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2015.0163-15 · Cited by 26
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J. A., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0492-6 · Cited by 24
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 31
McCullough, P. A., Ballantyne, C. M., Sanganalmath, S. K., Langslet, G., Baum, S. J., Shah, P. K., Koren, A., Mandel, J., & Davidson, M. H. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.12.040 · Cited by 25
Self-citationKodera, S., Morita, H., Kiyosue, A., Ando, J., Takura, T., & Komuro, I. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1455 · Cited by 25
Khan, S. U., Riaz, H., Rahman, H., Khan, M. U., Khan, M. S., Alkhouli, M. A., Kaluski, E., Leucker, T. M., & Blaha, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.014 · Cited by 26
Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
Rymer, J. A., Mues, K. E., Monda, K. L., Bratton, E. W., Wirtz, H. S., Okerson, T., Overman, R. A., Brookhart, M. A., Muntner, P., & Wang, T. Y. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014347 · Cited by 23
Inoue, K., Figueroa, J. F., DeJong, C., Tsugawa, Y., Orav, E. J., Shen, C., & Kazi, D. S. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007521 · Cited by 25
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
Ferdinand, K. C., & Nasser, S. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6588-3 · Cited by 24
A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease
Rogers, M. A., & Aïkawa, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018139 · Cited by 24
Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190326 · Cited by 23
Preventive Role of Tetraspanin CD9 in Systemic Inflammation of Chronic Obstructive Pulmonary Disease
Takeda, Y., Suzuki, M., Jin, Y., & Tachibana, I. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0122tr · Cited by 28
“16 inhibitory mAbs to PCSK9 and were recently shown to reduce LDL cholesterol levels and cardiovascular events (120, 121), might possibly upregulate CD9 as well as CD81, like lipophilic statins.”
BackgroundCho, L., Dent, R. E., Stroes, E. S. G., Stein, E. A., SULLIVAN, D. R., Ruzza, A., Flower, A., Somaratne, R. M., & Rosenson, R. S. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6817-7 · Cited by 25
Self-citationLDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis
Masson, W. M., Lobo, M., Siniawski, D. A., Masson, G., Cobo, A. L., & Molinero, G. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105655 · Cited by 23
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
Agarwala, A., Quispe, R., Goldberg, A. C., & Michos, E. D. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s251865 · Cited by 23
“Current adjuncts or alternatives to statin therapy include ezetimibe and PCSK9 inhibitors.(3,4) Ezetimibe is oral, affordable,”
BackgroundPharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Hindi, N. N., Alenbawi, J., & Nemer, G. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090877 · Cited by 24
“This differential efficacy was found in patients with heterozygous FH and those at high CVD risk and resistance to statins [67,72].”
BackgroundInflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease
Kon, V., Shelton, E. L., Pitzer, A. L., Yang, H., & Kirabo, A. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01206-4 · Cited by 23
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
“4% at week 72, along with an overall improvement in lipid profile including Lp(a) [73].”
BackgroundImpact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
González-Lleó, A. M., Sánchez-Hernández, R. M., Plana, N., Ibarretxe, D., Rehues, P., Ribalta, J., Llop, D., Wägner, A. M., Masana, L., & Boronat, M. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02077-y · Cited by 23
“These therapies lower LDL-C concentrations by approximately 60% and significantly reduce cardiovascular risk when added to statin therapy [3, 4].”
BackgroundThe Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms
Săvulescu-Fiedler, I., Dorobantu-Lungu, L.-R., Dragosloveanu, Ş., Benea, S. N., Dragosloveanu, C. D. M., Căruntu, A., Scheau, A.-E., Căruntu, C., & Scheau, C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020115 · Cited by 25
“Healthy diets are increasingly promoted and plant foods have shown effectiveness in cardiovascular disease prevention due to their low amounts of fats and bioactive compounds, which act as cholesterol-lowering agents via different mechanisms [363].”
Guo, T., Yin, R., Lin, W., Wang, W., Huang, F., & Pan, S. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12713 · Cited by 24
“Alirocumab, an inhibitor of PCSK9, significantly reduced levels of LDL-C when added to statin therapy administered at the maximum tolerated dose [52].”
BackgroundMasana, L., Ibarretxe, D., & Plana, N. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.11.014 · Cited by 28
Koh, K. K., Oh, P. C., Sakuma, I., Lee, Y., Han, S. H., & Shin, E. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.051 · Cited by 25
LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
Weitgasser, R., Ratzinger, M., Hemetsberger, M., & Siostrzonek, P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0518-2 · Cited by 25
Alkhalil, M., Biasiolli, L., Chai, J. T., Galassi, F., Li, L., DARBY, C. R., Halliday, A. W., Hands, L. J., Magee, T. R., Perkins, J. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181668 · Cited by 23
Hachem, A. A., Hariri, E. H., Saoud, P., Lteif, C., Lteif, L., & Welty, F. K. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170804150954 · Cited by 23
Sun, D., Li, S., Zhao, X., Wu, N., Zhu, C., Guo, Y., Gao, Y., Qing, P., Cui, C.-J., Liu, G., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.004 · Cited by 23
Soran, H., Adam, S., & Durrington, P. N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.040 · Cited by 23
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Chen, B., Shi, X., Cui, Y., Hou, A., & Zhao, P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809094203 · Cited by 23
Robinson, J. G., Farnier, M., Kastelein, J. J. P., Roth, E. M., Taskinen, M., Colhoun, H. M., Brunet, A., DiCioccio, A. T., Lecorps, G., Pordy, R. C., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.004 · Cited by 23
Self-citationClopidogrel drug interactions: a review of the evidence and clinical implications
Lee, C. H., Franchi, F., & Angiolillo, D. J. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1814254 · Cited by 23
Homozygous familial hypercholesterolemia: Summarized case reports
Widhalm, K., Benke, I. M., Fritz, M., Geiger, H., Helk, O., Fritsch, M., Hoermann, G., & Kostner, G. M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.01.002 · Cited by 23
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
Vrablík, M., Šarkanová, I., Breciková, K., Šedová, P., Šatný, M., & Tichopád, A. (2023) · PLOS ONE · doi:10.1371/journal.pone.0272883 · Cited by 22
Roubtsova, A., Garçon, D., Lacoste, S., Chamberland, A., Marcinkiewicz, J., Métivier, R., Sotin, T., Paquette, M., Bernard, S., Cariou, B., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159217 · Cited by 22
Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
Návar, A. M., Wang, T. Y., Goldberg, A. C., Robinson, J. G., Roger, V. L., Wilson, P. W. F., Virani, S. S., Elassal, J., Lee, L. V., Webb, L. E., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.08.002 · Cited by 23
Self-citationBusuioc, R., Covic, A. C., Kanbay, M., Banach, M., Burlacu, A., & Mircescu, G. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz108 · Cited by 22
Chen, Q., Wu, G., Li, C., Qin, X., Liu, R., & Zhang, M. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00386-w · Cited by 22
Liang, Z., Chen, Q., Yang, F., Yan, X., Zhang, X., Xue, C., Fang, F., & Zhao, Q. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07079-6 · Cited by 23
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 23
Common genetic risk factors for coronary artery disease: new opportunities for prevention?
Hamrefors, V. (2015) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12289 · Cited by 25
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 23
Teramoto, T., Kiyosue, A., Ishigaki, Y., Harada‐Shiba, M., Kawabata, Y., Ozaki, A., Baccara‐Dinet, M. T., & Sata, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.10.004 · Cited by 22
“The combination of statin plus alirocumab Q2W led to persistent reductions in LDL-C over the dosing interval [14,15,18,21], but these reductions were not fully sustained when alirocumab was given Q4W [13,15].”
BackgroundEffect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels
Ye, Q., Svatikova, A., Meeusen, J. W., Kludtke, E. L., & Kopecky, S. L. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.04.052 · Cited by 22
Ali, L., Cupido, A. J., Rijkers, M., Hovingh, G. K., Holleboom, A. G., Dallinga‐Thie, G. M., Stroes, E. S. G., & van den Boogert, M. A. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.001 · Cited by 23
Self-citationLandmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P. J., Arellano, J., Svensson, M. K. E., Sibartie, M., & Fonarow, G. C. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa072 · Cited by 22
Matsui, S., Kajikawa, M., Hida, E., Maruhashi, T., Iwamoto, Y., Iwamoto, A., Oda, N., Kishimoto, S., Hidaka, T., Kihara, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09043-1 · Cited by 22
Juričić, S., Klac, J., Stojkovic, S. M., Tesic, M. B., Jovanović, I., Aleksandric, S. B., Dobric, M. R., Živković, S., Maričić, B., Simeunović, D. S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093924 · Cited by 25
“…aldose reductase (AR), with the help of the coenzyme nicotinamide adenine dinucleotide phosphate (NADPH), reduces glucose to sorbitol [21,29,43,44]. the polyol pathway, the enzyme aldose reductase (AR), with the help of the coenzyme nicotinamide adenine dinucleotide phosphate (NADPH), reduces…”
Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial
Fearon, W. F., Terada, K., Takahashi, K., Skoda, A., Luikart, H. I., Lamendola, C. A., Zimmermann, F. M., Hashikata, T., Saito, K., 吉田明弘, et al. (2025) · Circulation · doi:10.1161/circulationaha.125.077603 · Cited by 22
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
Rallidis, L. S., & Lekakis, J. P. (2016) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2016.03.002 · Cited by 21
“02).(12) In addition, the OSLER (Open-Label Study of Long-Term Evaluation against LDL Cholesterol)-1 and OSLER-2 trials reported similar results.”
ResultKatsiki, N., Athyros, V. G., Mikhailidis, D. P., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.007 · Cited by 21
“[5] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators.”
BackgroundInfluentialThe Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
Patel, R. S., Scopelliti, E. M., & Olugbile, O. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018771670 · Cited by 21
Lipid management in ACS: Should we go lower faster?
Gencer, B., & Mach, F. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.871 · Cited by 24
Capodanno, D., Mehran, R., Gibson, C. M., & Angiolillo, D. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1543399 · Cited by 21
Cognitive Function in a Randomized Trial of Evolocumab
Giugliano, R. P., Mach, F., Zavitz, K. H., Kurtz, C. E., Im, K., Kanevsky, E., Schneider, J., Wang, H., KEECH, A. C., Pedersen, T. R., et al. (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.12.14 · Cited by 21
Self-citationCurrent pharmacotherapies for atherosclerotic cardiovascular diseases
Park, J., & Oh, G. T. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01116-1 · Cited by 21
Yan, R., Gu, H., Wang, W., Ma, L., & Li, W. (2019) · Hypertension Research · doi:10.1038/s41440-019-0281-z · Cited by 21
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 23
Siew, W. S., Tang, Y.-Q., Kong, C. K., Goh, B. H., Zacchigna, S., Dua, K., Chellappan, D. K., Duangjai, A., Saokaew, S., Phisalprapa, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168422 · Cited by 21
“PCSK9 inhibitors such as evolocumab [7–9], alirocumab [10] that target PCSK9 enzyme have been tested in clinical trials and showed efficacy in lowering LDL cholesterol levels.”
BackgroundA Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody
Cui, Y., Zhao, X., Qi, L., Li, X., Huang, Z., Yang, G., Qian, L., Deng, H., Li, H., & Huo, Y. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.09.002 · Cited by 21
“Both were administered every 24 weeks and reduced LDL-C levels by approximately 60% (4,5).”
Background
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.